NCT05705505View on ClinicalTrials.gov

Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 29, 2023

Primary Completion Date

January 31, 2026

Study Completion Date

February 28, 2026

Conditions
Endometrioid Endometrial Cancer
Interventions
DRUG

Narazaciclib

Orange tablets, each containing 40 mg or 120 mg of narazaciclib as narazaciclib monolactate

DRUG

Letrozole 2.5mg

Tablet

Trial Locations (8)

10016

RECRUITING

NYU Langone, New York

11501

RECRUITING

Perlmutter Cancer Center at NYU Langone Hospital - Long Island, Mineola

29605

RECRUITING

Greenville Health System, Institute for Oncology Clinical Research, Greenville

55404

RECRUITING

Minnesota Oncology Hematology, P.A., Minneapolis

75246

RECRUITING

Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas

76104

RECRUITING

Texas Oncology - Fort Worth Cancer Center, Fort Worth

85711

RECRUITING

Arizona Oncology Associates, PC - HOPE, Tucson

97401

RECRUITING

Willamette Valley Cancer Institute and Research Center, Eugene

All Listed Sponsors
lead

Traws Pharma, Inc.

INDUSTRY